Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma
Open Access
- 1 November 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 11 (11) , 1471-1476
- https://doi.org/10.1023/a:1026556119020
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- MDR1 gene expression in solid tumoursEuropean Journal Of Cancer, 1996
- Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisersEuropean Journal Of Cancer, 1996
- Clinical trials of p-glycoprotein reversal in solid tumoursEuropean Journal Of Cancer, 1996
- Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical OutcomeNew England Journal of Medicine, 1995
- Systemic Toxic Effects Associated With High-Dose Verapamil Infusion and Chemotherapy AdministrationJNCI Journal of the National Cancer Institute, 1991
- VerapamilDrugs, 1989
- Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenograftsBiochemical Pharmacology, 1989
- Reversal of drug‐resistance in multiple myeloma with verapamilBritish Journal of Haematology, 1988
- Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistanceNature, 1986